Invention Grant
- Patent Title: Nitrogenated heterocyclic compound
-
Application No.: US15264213Application Date: 2016-09-13
-
Publication No.: US10017508B2Publication Date: 2018-07-10
- Inventor: Satoshi Mikami , Shinji Nakamura , Tomoko Ashizawa , Shigekazu Sasaki , Takahiko Taniguchi , Izumi Nomura , Masanori Kawasaki
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Hamre, Schumann, Mueller & Larson, P.C.
- Priority: JP2012-100374 20120425; JP2012-283470 20121226
- Main IPC: C07D241/36
- IPC: C07D241/36 ; A61K31/498 ; C07D471/04 ; C07D519/00 ; A61K9/20 ; A61K31/555 ; C07F7/18
Abstract:
The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
Public/Granted literature
- US20170129887A1 NITROGENATED HETEROCYCLIC COMPOUND Public/Granted day:2017-05-11
Information query
